Once-Daily Tacrolimus Extended-Release Formulation: 1 Year after Conversion in Stable Pediatric Kidney Transplant Recipients
It is speculated that a once-daily dosage of immunosuppression can increase adherence and thereby graft survival. Until now, there have been no studies on once-daily use of Tacrolimus extended-release formulation (TAC-ER) in children following pediatric kidney transplantation. In 11 stable pediatric...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | International Journal of Nephrology |
| Online Access: | http://dx.doi.org/10.4061/2011/126251 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849685190387957760 |
|---|---|
| author | Lars Pape Nele Heidotting Thurid Ahlenstiel |
| author_facet | Lars Pape Nele Heidotting Thurid Ahlenstiel |
| author_sort | Lars Pape |
| collection | DOAJ |
| description | It is speculated that a once-daily dosage of immunosuppression can increase adherence and thereby graft survival. Until now, there have been no studies on once-daily use of Tacrolimus extended-release formulation (TAC-ER) in children following pediatric kidney transplantation. In 11 stable pediatric kidney recipients >10 years, efficacy, safety, and tolerability of a switch to TAC-ER were observed over one year. Adherence was determined by use of the BAASIS-Scale Interview and comparison of individual variability of Tacrolimus trough levels. Over the observation period, two acute rejections were observed in one girl with nonadherence and repeated Tacrolimus trough levels of 0 ng/m. Beside this, there were no acute rejections in this trial. TAC dose was increased in 3/11 patients and decreased in 2/11 patients within the course of the study. Six patients did not require a dose adjustment. All but one patient had a maximum of 1 dose change during therapy. Mean Tacrolimus dose, trough levels, and Glomerular filtration rates were also stable. Adherence, as measured by BAASIS-Scale Interview and coefficient of variation of Tacrolimus trough levels, was good at all times. It is concluded that conversion to Tac-ER is safe in low-risk children following pediatric kidney transplantation. |
| format | Article |
| id | doaj-art-b9521650fc4b42ec852ed5bfe0ec63e5 |
| institution | DOAJ |
| issn | 2090-214X 2090-2158 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Nephrology |
| spelling | doaj-art-b9521650fc4b42ec852ed5bfe0ec63e52025-08-20T03:23:14ZengWileyInternational Journal of Nephrology2090-214X2090-21582011-01-01201110.4061/2011/126251126251Once-Daily Tacrolimus Extended-Release Formulation: 1 Year after Conversion in Stable Pediatric Kidney Transplant RecipientsLars Pape0Nele Heidotting1Thurid Ahlenstiel2Department of Pediatric Nephrology, Hannover Medical School, 30625 Hannover, GermanyDepartment of Pediatric Nephrology, Hannover Medical School, 30625 Hannover, GermanyDepartment of Pediatric Nephrology, Hannover Medical School, 30625 Hannover, GermanyIt is speculated that a once-daily dosage of immunosuppression can increase adherence and thereby graft survival. Until now, there have been no studies on once-daily use of Tacrolimus extended-release formulation (TAC-ER) in children following pediatric kidney transplantation. In 11 stable pediatric kidney recipients >10 years, efficacy, safety, and tolerability of a switch to TAC-ER were observed over one year. Adherence was determined by use of the BAASIS-Scale Interview and comparison of individual variability of Tacrolimus trough levels. Over the observation period, two acute rejections were observed in one girl with nonadherence and repeated Tacrolimus trough levels of 0 ng/m. Beside this, there were no acute rejections in this trial. TAC dose was increased in 3/11 patients and decreased in 2/11 patients within the course of the study. Six patients did not require a dose adjustment. All but one patient had a maximum of 1 dose change during therapy. Mean Tacrolimus dose, trough levels, and Glomerular filtration rates were also stable. Adherence, as measured by BAASIS-Scale Interview and coefficient of variation of Tacrolimus trough levels, was good at all times. It is concluded that conversion to Tac-ER is safe in low-risk children following pediatric kidney transplantation.http://dx.doi.org/10.4061/2011/126251 |
| spellingShingle | Lars Pape Nele Heidotting Thurid Ahlenstiel Once-Daily Tacrolimus Extended-Release Formulation: 1 Year after Conversion in Stable Pediatric Kidney Transplant Recipients International Journal of Nephrology |
| title | Once-Daily Tacrolimus Extended-Release Formulation: 1 Year after Conversion in Stable Pediatric Kidney Transplant Recipients |
| title_full | Once-Daily Tacrolimus Extended-Release Formulation: 1 Year after Conversion in Stable Pediatric Kidney Transplant Recipients |
| title_fullStr | Once-Daily Tacrolimus Extended-Release Formulation: 1 Year after Conversion in Stable Pediatric Kidney Transplant Recipients |
| title_full_unstemmed | Once-Daily Tacrolimus Extended-Release Formulation: 1 Year after Conversion in Stable Pediatric Kidney Transplant Recipients |
| title_short | Once-Daily Tacrolimus Extended-Release Formulation: 1 Year after Conversion in Stable Pediatric Kidney Transplant Recipients |
| title_sort | once daily tacrolimus extended release formulation 1 year after conversion in stable pediatric kidney transplant recipients |
| url | http://dx.doi.org/10.4061/2011/126251 |
| work_keys_str_mv | AT larspape oncedailytacrolimusextendedreleaseformulation1yearafterconversioninstablepediatrickidneytransplantrecipients AT neleheidotting oncedailytacrolimusextendedreleaseformulation1yearafterconversioninstablepediatrickidneytransplantrecipients AT thuridahlenstiel oncedailytacrolimusextendedreleaseformulation1yearafterconversioninstablepediatrickidneytransplantrecipients |